Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Immortals vs Transparent Meds

Immortals
Graded #286

Lower grade

vs+0.10000000000000142
Transparent Meds
Graded #284

Higher grade

The verdict

Transparent Meds takes it — 61.9/100 to 61.8/100, but only just.

Transparent Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Transparent Meds is an online GLP-1 weight-care service that connects you with licensed medical providers and leads with upfront pricing: compounded weekly injections of semaglutide at an intro $149/month… Immortals is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueImmortals +11
54
43
Dose & formulationTransparent Meds +13
64
77
Clinical oversightImmortals +9
88
79
Labs & monitoringImmortals +2
54
52
FulfillmentTransparent Meds +6
68
74
Contract termsTransparent Meds +21
20
41
Immortals · left barTransparent Meds · right bar

The numbers

MetricImmortalsTransparent Meds
WeighScore61.8/10061.9/100
GradeCC
Scorecard rank#286#284
Semaglutide$167/mo (microdose tier, compounded)$229/mo (promotional rate, compounded)
Tirzepatide$180/mo (microdose tier, compounded)$349/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Immortals

Graded #286 · C

Strengths

  • LegitScript certified (ID 50458743) with board-certified U.S. physician review within 72 hours
  • Physician consult + prescription bundled in price — 'You pay for treatment. That's it' with no added fees
  • Competitive pricing: semaglutide microdose from $167/month, tirzepatide from $180/month (promotional)
  • Unlimited provider messaging for 12 months included; video consults available
  • Founded by Bryan Johnson and Kate Tolo; clinical lead Dr. Carl Seger, M.D. (preventive/longevity medicine)

Where it loses points

  • Microdose framing uses sub-clinical doses — lower weight-loss efficacy than standard GLP-1 protocols
  • Quarterly commitment only — 3-month minimum, paid upfront ($501–$540/quarter); no monthly flexibility
  • State availability not publicly listed; 'eligible U.S. states' with no specific state list
  • Labs not included; baseline bloodwork protocol not disclosed on any public page
  • Compounding pharmacy not named; no 503A/503B accreditation details disclosed
Transparent Meds

Graded #284 · C

Strengths

  • Transparent, upfront monthly pricing — intro $149/mo for compounded semaglutide and $249/mo for tirzepatide (regular $229 / $349)
  • Clean, modern telehealth experience with a quick eligibility quiz and clinician review before any prescription
  • HIPAA-compliant and displays a LegitScript-style verification seal

Where it loses points

  • Headline prices are intro first-month fees — the regular monthly cost is higher ($229 semaglutide, $349 tirzepatide)
  • Connector model that pairs you with licensed providers; it doesn't name its compounding pharmacy
  • Doesn't publish the states it serves, so confirm availability before signing up
  • Compounded semaglutide and tirzepatide injections only — no oral, brand-name, or insurance options

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard